Literature DB >> 25692621

Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells.

Sonam Dilwali1, Daniel Roberts, Konstantina M Stankovic.   

Abstract

Vestibular schwannoma (VS), the fourth most common intracranial tumor, arises from the Schwann cells of the vestibular nerve. Although several pathways have been independently implicated in VS pathobiology, interactions among these pathways have not been explored in depth. We have investigated the potential cross-talk between hepatocyte growth factor (HGF) and vascular endothelial growth factor-A (VEGF-A) in human VS, an interaction that has been described in other physiological and pathological cell types. We affirmed previous findings that VEGF-A signaling is aberrantly upregulated in VS, and established that expression of HGF and its receptor cMET is also significantly higher in sporadic VS than in healthy nerves. In primary human VS and Schwann cell cultures, we found that VEGF-A and HGF signaling pathways modulate each other. siRNAs targeting cMET decreased both cMET and VEGF-A protein levels, and siRNAs targeting VEGF-A reduced cMET expression. Additionally, siRNA-mediated knockdown of VEGF-A or cMET and pharmacologic inhibition of cMET decreased cellular proliferation in primary human VS cultures. Our data suggest cross-talk between these 2 prominent pathways in VS and highlight the HGF/cMET pathway as an additional important therapeutic target in VS.

Entities:  

Keywords:  BrdU, 5-Bromo-2'-Deoxyuridine; DMSO, Dimethyl sulfoxide; GAN, Great auricular nerve; HCl, Hydrochloric acid; HGF, Gene encoding HGF protein; HGF, Hepatocyte growth factor; HRP, Horse-radish peroxidase; KDR, Gene encoding vascular endothelial growth factor receptor 2; MET, Gene encoding cMET protein; NF2, Neurofibromatosis type 2; PBS, Phosphate buffered saline; S100, Schwann cell/schwannoma cell marker; SD, Standard deviation; SEM, Standard error of mean; Schwann cells; VEGF-A, Vascular endothelial growth factor-A; VEGFA, Gene encoding VEGF-A protein; VEGFR2, Vascular endothelial growth factor receptor 2; VS, Vestibular schwannoma; cMET, MNNG HOS transforming gene, hepatocyte growth factor receptor; cross-talk; hepatocyte growth factor; mRNA, Messenger ribonucleic acid; siRNA; siRNA, Small interfering ribonucleic acid; vascular endothelial growth factor; vestibular schwannoma

Mesh:

Substances:

Year:  2015        PMID: 25692621      PMCID: PMC4622023          DOI: 10.4161/15384047.2014.972765

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  15 in total

1.  Analysis of patterns of care of brain tumor patients in the United States: a study of the Brain Tumor Section of the AANS and the CNS and the Commission on Cancer of the ACS.

Authors:  M S Mahaley; C Mettlin; N Natarajan; E R Laws; B B Peace
Journal:  Clin Neurosurg       Date:  1990

2.  HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells.

Authors:  Atsushi Matsumura; Takeshi Kubota; Hiroaki Taiyoh; Hitoshi Fujiwara; Kazuma Okamoto; Daisuke Ichikawa; Atsushi Shiozaki; Shuhei Komatsu; Masayoshi Nakanishi; Yoshiaki Kuriu; Yasutoshi Murayama; Hisashi Ikoma; Toshiya Ochiai; Yukihito Kokuba; Takahiro Nakamura; Kunio Matsumoto; Eigo Otsuji
Journal:  Int J Oncol       Date:  2012-12-06       Impact factor: 5.650

3.  Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans.

Authors:  T Moriyama; H Kataoka; H Kawano; K Yokogami; S Nakano; T Goya; H Uchino; M Koono; S Wakisaka
Journal:  Cancer Lett       Date:  1998-02-27       Impact factor: 8.679

4.  VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate.

Authors:  Per Cayé-Thomasen; Kim Werther; Amarnadh Nalla; Thorkild C Bøg-Hansen; Hans Jørgen Nielsen; Sven-Eric Stangerup; Jens Thomsen
Journal:  Otol Neurotol       Date:  2005-01       Impact factor: 2.311

5.  Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells.

Authors:  T Moriyama; H Kataoka; R Hamasuna; K Yokogami; H Uehara; H Kawano; T Goya; H Tsubouchi; M Koono; S Wakisaka
Journal:  Biochem Biophys Res Commun       Date:  1998-08-10       Impact factor: 3.575

6.  Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET?

Authors:  Joseph H McCarty
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

7.  Potentiation by platelet-derived growth factor-BB of FGF-2-stimulated VEGF release in osteoblasts.

Authors:  Haruhiko Tokuda; Shinji Takai; Yoshiteru Hanai; Atsushi Harada; Rie Matsushima-Nishiwaki; Hisaaki Kato; Shinji Ogura; Osamu Kozawa
Journal:  J Bone Miner Metab       Date:  2008-07-04       Impact factor: 2.626

8.  Primary culture of human Schwann and schwannoma cells: improved and simplified protocol.

Authors:  Sonam Dilwali; Pratik B Patel; Daniel S Roberts; Gina M Basinsky; Gordon J Harris; Kevin S Emerick; Konstantina M Stankovic
Journal:  Hear Res       Date:  2014-06-06       Impact factor: 3.208

9.  Sporadic vestibular schwannomas associated with good hearing secrete higher levels of fibroblast growth factor 2 than those associated with poor hearing irrespective of tumor size.

Authors:  Sonam Dilwali; Andrew Lysaght; Daniel Roberts; Fred G Barker; Michael J McKenna; Konstantina M Stankovic
Journal:  Otol Neurotol       Date:  2013-06       Impact factor: 2.311

10.  The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.

Authors:  Christopher H Lieu; Hai Tran; Zhi-Qin Jiang; Muling Mao; Michael J Overman; E Lin; Cathy Eng; Jeffrey Morris; Lee Ellis; John V Heymach; Scott Kopetz
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

View more
  8 in total

1.  Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.

Authors:  Yingchao Zhao; Pinan Liu; Na Zhang; Jie Chen; Lukas D Landegger; Limeng Wu; Fu Zhao; Yanxia Zhao; Yanling Zhang; Jing Zhang; Takeshi Fujita; Anat Stemmer-Rachamimov; Gino B Ferraro; Hao Liu; Alona Muzikansky; Scott R Plotkin; Konstantina M Stankovic; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-09       Impact factor: 11.205

2.  A Unified Methodological Framework for Vestibular Schwannoma Research.

Authors:  Lukas D Landegger; Jessica E Sagers; Sonam Dilwali; Takeshi Fujita; Mehmet I Sahin; Konstantina M Stankovic
Journal:  J Vis Exp       Date:  2017-06-20       Impact factor: 1.355

Review 3.  A Critical Overview of Targeted Therapies for Vestibular Schwannoma.

Authors:  Ryota Tamura; Masahiro Toda
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

4.  A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.

Authors:  Jeffrey R Gehlhausen; Eric Hawley; Benjamin Mark Wahle; Yongzheng He; Donna Edwards; Steven D Rhodes; Jacquelyn D Lajiness; Karl Staser; Shi Chen; Xianlin Yang; Jin Yuan; Xiaohong Li; Li Jiang; Abbi Smith; Waylan Bessler; George Sandusky; Anat Stemmer-Rachamimov; Timothy J Stuhlmiller; Steven P Angus; Gary L Johnson; Grzegorz Nalepa; Charles W Yates; D Wade Clapp; Su-Jung Park
Journal:  Hum Mol Genet       Date:  2019-02-15       Impact factor: 6.150

5.  Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.

Authors:  Sonam Dilwali; Lukas D Landegger; Vitor Y R Soares; Daniel G Deschler; Konstantina M Stankovic
Journal:  Sci Rep       Date:  2015-12-22       Impact factor: 4.379

6.  MicroRNA-4316 inhibits gastric cancer proliferation and migration via directly targeting VEGF-A.

Authors:  Haithm Mousa; Menglang Yuan; Xinsheng Zhang; Xiaomeng Li; Abdullah Shopit; Marwan Almoiliqy; Mohammed Alshwmi; Aisha Al-Dherasi; Yue Xu; Yunfei Zuo
Journal:  Cancer Cell Int       Date:  2020-02-22       Impact factor: 5.722

Review 7.  New developments in neurofibromatosis type 2 and vestibular schwannoma.

Authors:  Yin Ren; Divya A Chari; Sasa Vasilijic; D Bradley Welling; Konstantina M Stankovic
Journal:  Neurooncol Adv       Date:  2020-11-16

8.  Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.

Authors:  Jessica E Sagers; Roberta L Beauchamp; Yanling Zhang; Sasa Vasilijic; Limeng Wu; Patrick DeSouza; Richard Seist; Wenjianlong Zhou; Lei Xu; Vijaya Ramesh; Konstantina M Stankovic
Journal:  Sci Rep       Date:  2020-03-06       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.